Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 4 | 2021 | 154 | 1.110 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2021 | 70 | 1.010 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1573 | 0.850 |
Why?
|
| Paranasal Sinuses | 1 | 2021 | 269 | 0.680 |
Why?
|
| Nose | 1 | 2021 | 493 | 0.630 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 369 | 0.590 |
Why?
|
| Neutropenia | 1 | 2020 | 875 | 0.580 |
Why?
|
| Vancomycin | 1 | 2019 | 502 | 0.560 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2021 | 331 | 0.480 |
Why?
|
| Fever | 1 | 2020 | 1589 | 0.480 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 2109 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2101 | 0.410 |
Why?
|
| Nephrosis, Lipoid | 2 | 2020 | 51 | 0.410 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 2986 | 0.370 |
Why?
|
| Sepsis | 1 | 2020 | 2474 | 0.310 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 1890 | 0.300 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 2189 | 0.270 |
Why?
|
| Vaginal Discharge | 1 | 2021 | 22 | 0.220 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2021 | 25 | 0.220 |
Why?
|
| Vaginitis | 1 | 2021 | 47 | 0.220 |
Why?
|
| Filgrastim | 1 | 2020 | 134 | 0.210 |
Why?
|
| Hematologic Agents | 1 | 2020 | 40 | 0.200 |
Why?
|
| Azathioprine | 1 | 2020 | 334 | 0.190 |
Why?
|
| Mycophenolic Acid | 1 | 2020 | 345 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2021 | 23511 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 577 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20398 | 0.160 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 235 | 0.150 |
Why?
|
| Prednisone | 1 | 2021 | 1549 | 0.150 |
Why?
|
| Optic Atrophy | 1 | 2014 | 65 | 0.130 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2014 | 79 | 0.130 |
Why?
|
| Muscle Spasticity | 1 | 2014 | 146 | 0.130 |
Why?
|
| Methotrexate | 1 | 2020 | 1723 | 0.130 |
Why?
|
| Trisomy | 1 | 2014 | 261 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2021 | 72255 | 0.120 |
Why?
|
| Sinusitis | 1 | 2021 | 883 | 0.110 |
Why?
|
| Recurrence | 2 | 2020 | 8269 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2018 | 1509 | 0.110 |
Why?
|
| Incidence | 2 | 2020 | 20596 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 4208 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6538 | 0.100 |
Why?
|
| Genetic Linkage | 1 | 2014 | 2516 | 0.090 |
Why?
|
| Multiple System Atrophy | 1 | 2009 | 85 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 2109 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39285 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 29168 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4918 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 4139 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 11285 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 12404 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5133 | 0.070 |
Why?
|
| Adult | 5 | 2021 | 212129 | 0.070 |
Why?
|
| Humans | 12 | 2021 | 715124 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 70704 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 684 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 17395 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13302 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 11402 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7045 | 0.050 |
Why?
|
| Female | 6 | 2021 | 377334 | 0.050 |
Why?
|
| Hospitalization | 1 | 2019 | 9718 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 214871 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 2020 | 392 | 0.040 |
Why?
|
| Time Factors | 1 | 2019 | 41081 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2009 | 2665 | 0.040 |
Why?
|
| Male | 5 | 2021 | 351081 | 0.030 |
Why?
|
| United States | 2 | 2021 | 67665 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 62186 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 162674 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 15584 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2009 | 6658 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 418 | 0.030 |
Why?
|
| France | 1 | 2014 | 488 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2009 | 3713 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 12921 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 4722 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 4824 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 1365 | 0.020 |
Why?
|
| Medicare | 1 | 2021 | 5759 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2021 | 39804 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2009 | 11907 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16371 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9772 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2009 | 9968 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 56155 | 0.010 |
Why?
|
Concepts
(85)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_